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Abstract
Background:  The acute coronary syndrome diagnosis includes different classifications of
myocardial infarction, which have been shown to differ in their pathology, as well as their early and
late prognosis. These differences may relate to the underlying extent of infarction and/or residual
myocardial ischemia. The study aim was to compare scar and ischemia mass between acute non-
ST elevation myocardial infarction (NSTEMI), ST-elevation MI with Q-wave formation (Q-STEMI)
and ST-elevation MI without Q-wave formation (Non-Q STEMI) in-vivo, using cardiovascular
magnetic resonance (CMR).
Methods and results: This was a prospective cohort study of twenty five consecutive patients
with NSTEMI, 25 patients with thrombolysed Q-STEMI and 25 patients with thrombolysed Non-
Q STEMI. Myocardial function (cine imaging), ischemia (adenosine stress first pass myocardial
perfusion) and scar (late gadolinium enhancement) were assessed by CMR 2–6 days after
presentation and before any invasive revascularisation procedure. All subjects gave written
informed consent and ethical committee approval was obtained. Scar mass was highest in Q-STEMI,
followed by Non-Q STEMI and NSTEMI (24.1%, 15.2% and 3.8% of LV mass, respectively; p <
0.0001). Ischemia mass showed the reverse trend and was lowest in Q-STEMI, followed by Non-
Q STEMI and NSTEMI (6.9%, 14.7% and 19.9% of LV mass, respectively; p = 0.012). The combined
mass of scar and ischemia was similar between the three groups (p = 0.17). The ratio of scar to
ischemia was 3.5, 1.0 and 0.2 for Q-STEMI, Non-Q STEMI and NSTEMI, respectively.
Conclusion: Prior to revascularisation, the ratio of scar to ischemia differs between NSTEMI,
Non-Q STEMI and Q-STEMI, whilst the combined scar and ischemia mass is similar between these
three types of MI. These results provide in-vivo confirmation of the diverse pathophysiology of
different types of acute myocardial infarction and may explain their divergent early and late
prognosis.
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Background
The acute coronary syndromes encompass ST-elevation
myocardial infarction (STEMI), non-ST elevation myocar-
dial infarction (NSTEMI) and unstable angina [1,2].
STEMI is typically the consequence of a complete occlu-
sion of the culprit artery with an ultimately fibrin-rich
thrombus, whilst NSTEMI is caused by a transient coro-
nary occlusion or of micro-embolisation with compo-
nents of a non-occlusive, often platelet-rich thrombus
[2,3]. As a consequence of these pathophysiological dif-
ferences, STEMI generally results in larger infarction than
NSTEMI [4-6]. Q-waves on an electrocardiogram develop
in approximately two thirds of STEMIs, largely dependent
on infarct size, but Q-wave development is rare after
NSTEMI [7-10].
Whether myocardium supplied by the infarct-related
artery remains at risk of further ischemia following acute
myocardial infarction (MI) depends largely on the pres-
ence of a flow-limiting lesion in the culprit vessel. Further-
more, the amount of viable myocardium remaining at
ischemic risk from the culprit lesion is related to the extent
of infarcted myocardium; the larger the infarct, the less is
left to be at risk of ischemia. Before revascularisation, the
combined mass of scar and ischemia represents the total
myocardium at risk and should be similar between differ-
ent types of MI. These basic concepts have not been fully
studied in-vivo. In previous studies, scar and ischemia
burden after Q-wave and Non-Q wave MI have been com-
pared in segmental models using nuclear scintigraphy
[11,12]. Similar comparisons between STEMI and
NSTEMI have not been undertaken and quantitative com-
parisons of scar and ischemia mass are not available.
Cardiovascular magnetic resonance (CMR) offers a poten-
tially more accurate technique for in-vivo comparisons of
ischemia, function and scar than nuclear scintigraphy.
CMR provides images with high spatial resolution, free of
geometric constraints, as well as precise volumetric quan-
tification of abnormalities and direct anatomical correla-
tion [13-15]. In particular, first-pass stress myocardial
perfusion and late gadolinium-enhancement imaging
offer emerging tools for the in-vivo assessment of coro-
nary heart disease. In this study we used CMR to test the
hypothesis that the combined mass of scar and inducible
ischemia is similar in NSTEMI, Q-STEMI and Non-Q
STEMI reflecting a similar amount of myocardium at risk,
but that the ratio of scar to ischemia differs according to
the pathophysiology of the infarct.
Methods
Subjects
All patients presenting to our institution with a troponin-
positive acute coronary syndrome were eligible for study
inclusion. Exclusion criteria were previous MI, NYHA
class-IV heart failure, ongoing ischemic symptoms, con-
traindications to CMR or adenosine infusion. All patients
gave informed written consent to study protocols
approved by our local ethics committee. Patients were
prospectively recruited 48-hours after presentation into
three predefined groups of NSTEMI, Non-Q STEMI and
Q-STEMI. Recruitment into each group was consecutive
and unselected until 25 patients were enrolled into each
group. The recruitment period was 12 months for
NSTEMI, 17 months for Non-Q STEMI and 8 months for
the Q-STEMI groups. The groups were defined as follows:
NSTEMI patients had chest pain, no ST elevation on the
presenting 12-lead electrocardiogram and elevated tro-
ponin levels [16]. According to local protocols patients
were initially treated with intensive medical therapy that
included aspirin, clopidogrel, heparin and glycoprotein
IIb/IIIa inhibitors when indicated. After 2–6 days, they
underwent X-ray coronary angiography with the intention
to perform revascularisation if required.
Non-Q STEMI patients presented with a first ST-elevation
MI according to standard criteria [15]. According to the
standard of care at our institution at the time, all STEMI
patients were initially treated with intravenous thrombol-
ysis. They underwent X-ray angiography during the index
admission only if there was evidence of ischemia [17].
Patients requiring rescue angioplasty were excluded.
Patients were recruited to this group if serial electrocardi-
ograms did not show the formation of pathological Q-
waves [16].
Q-STEMI patients presented and were managed analo-
gous to the Non-Q STEMI group. They were recruited into
this group if they developed pathological Q-waves on
serial electrocardiograms over 48 hours [16].
CMR
All patients underwent CMR between days 2–6 of admis-
sion prior to X-ray angiography. CMR studies were carried
out on a clinical 1.5 Tesla system (Gyroscan NT Intera CV,
Philips Medical Systems, Best, The Netherlands). Heart
rate, vectorcardiogram and blood pressure were moni-
tored. The CMR protocol has been described in detail pre-
viously [18-21]. It included assessment of LV function,
first-pass contrast-enhanced myocardial perfusion at rest
and during adenosine-stress as well as late gadolinium-
enhanced imaging for the assessment of viability and scar.
All data were acquired in LV short axis. First pass myocar-
dial perfusion imaging was carried out at rest and during
a five minute adenosine infusion (140 mcg/kg/min). A
bolus of 0.05 mmol/kg dimeglumine gadopentetate was
given at 6 ml/s by power injector (Spectris, Medrad, Pitts-
burgh, PA, USA) for each perfusion study and a T1-
weighted saturation recovery segmented k-space gradientJournal of Cardiovascular Magnetic Resonance 2008, 10:47 http://www.jcmr-online.com/content/10/1/47
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echo pulse sequence used for data acquisition (repetition
time/echo time 3.3/1.6 msec, flip angle 15°, SENSE factor
2, matrix 160 × 112 reconstructed to 256 × 256, spatial
resolution 3 × 3 × 8 mm, four slices acquired at each RR
interval with a variable interslice gap to cover the LV
between apex and base). LV function was assessed with a
cine steady state free precession pulse sequence covering
the whole LV in 10–12 contiguous slices (repetition time/
echo time 2.8/1.4 msec, flip angle 55°, spatial resolution
2 × 2 × 10 mm). Late gadolinium enhancement imaging
was performed 10 minutes after the final contrast bolus
injection (total dose 0.2 mmol/kg) using an inversion
recovery segmented k-space gradient echo pulse sequence
(repetition time/echo time 7.5/3.8 msec, flip angle 15°,
identical geometry to LV cine images, spatial resolution
1.3 × 1.3 × 10 mm, inversion time set to null signal from
normal myocardium).
Perfusion imaging in this study covered the LV in four
short axis slices with a variable interslice gap, whilst late
gadolinium-enhanced imaging provided LV coverage in
10–12 slices with no interslice gap. This approach was
necessary because with current CMR technology the
number of slices that can be acquired in first pass per-
fusion studies is limited unless sacrifices in temporal res-
olution, in-plane spatial resolution or other determinants
of image quality are made. For this study we regarded in-
plane spatial resolution and good image quality as more
relevant than acquiring additional slices in the perfusion
studies. In order to establish the potential bias introduced
by comparing the full-coverage late gadolinium-enhanced
imaging with the four-slice perfusion assessment, 10 ran-
domly selected late gadolinium-enhanced data sets were
analysed further. The data were reanalysed using only 4
slices with a 10 mm interslice gap (as would be typical for
a perfusion study) and following interpolation, absolute
LV mass, scar mass and percentage scar mass calculated.
Compared with the full-coverage data sets, no significant
differences were seen in percentage scar mass of the deci-
mated data sets (mean error: 0.4% p = 0.42).
CMR analysis
Analysis was performed using Mass 5.0 software (Medis,
Leiden, The Netherlands). On the cine images LV endocar-
dial and epicardial borders were outlined in diastole and
systole. Ischemia was defined visually as reduced or
delayed contrast uptake on stress perfusion images in
myocardium outside of the scar zone (on corresponding
late gadolinium enhancement images). Ischemic myocar-
dium in the infarct related artery territory only, as well as
LV endocardial and epicardial borders were outlined man-
ually with separate contours. On late gadolinium-
enhanced images, areas of enhanced myocardium (signal
intensity more than 2SD above normal myocardium)
were outlined as previously described [15]. Finally,
images were segmented according to the America Heart
Association classification [22].
Using manual planimetry and summation of discs meth-
odology, LV volumes, ejection fraction and LV mass were
calculated from the cine images covering the whole heart.
Ischemia mass and the LV myocardial mass covered by the
perfusion images were calculated. Likewise, scar and LV
myocardial mass covered by the late gadolinium enhance-
ment images were computed. Values were expressed as
absolute mass (g) and as percentage of LV mass relative to
the total myocardium covered by the respective acquisi-
tion. The ratio of ischemia to scar was calculated by divid-
ing percentage ischemia by percentage scar.
X-ray angiography
Cardiac catheterization was carried out using a standard
clinical technique and was reported by a blinded interven-
tional cardiologist. The presence of one or more coronary
stenoses of >70% luminal narrowing in a main coronary
vessel or major side branch of >2 mm diameter was
reported as significant. The 'culprit lesion' was defined on
the basis of angiographic characteristics, regional wall
motion abnormality and location of ECG changes.
Statistical analysis
Continuous variables are presented as mean ± SD, and
compared using one way analysis of variance with Bonfer-
roni multiple post test comparisons. Categorical data are
presented as number (%) and compared using a chi-
square test. The least square technique was used to assess
the linear relationship between variables. All statistical
tests were 2-sided and performed at the 5% significance
level.
Results
Clinical characteristics
The study group consisted of 75 patients; 25 recruited
consecutively into the three groups of NSTEMI, Non-Q
STEMI, Q-STEMI; demographics are listed in Table 1.
There were no significant differences in age, gender, risk
factors or presenting characteristics in multiple compari-
sons between the three groups.
The time between symptom onset and thrombolysis was
244 ± 208 min in the Q-STEMI and 168 ± 157 min in the
Non-Q STEMI group (p = 0.15). Biomarkers of myocar-
dial damage were significantly lower in the NSTEMI com-
pared with the Non-Q STEMI and Q-STEMI groups
(troponin-I 5.9, 29.6 and 69.9 mg/ml, respectively, p <
0.0001; peak CK 396, 1289, 2253IU, respectively, p <
0.0001) (Table 2). Infarct location was anterior in 12 and
inferior/lateral in 13 of Q-STEMIs and anterior in 8 and
inferior/lateral in 17 of Non-Q STEMIs.Journal of Cardiovascular Magnetic Resonance 2008, 10:47 http://www.jcmr-online.com/content/10/1/47
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X-ray coronary angiography was carried out in all patients
in the NSTEMI group, 19 in the Non-Q STEMI and 18 in
the Q-STEMI group. Table 3 shows the disease distribu-
tion and culprit lesion location. Three patients in both
STEMI groups had persistently occluded culprit vessels. By
chi-square analysis, there were no significant differences
between the three groups (NSTEMI, Non-Q STEMI, Q-
STEMI) in terms of their angiographic distribution of ves-
sels with significant stenosis, location of the culprit lesion,
or the disease extent (single, two-vessel or three-vessel dis-
ease).
CMR
No events occurred between recruitment and CMR, and
all 75 CMR studies were completed. The results for LV
function parameters are listed in Table 2. Total LV mass
and end diastolic volumes were similar between all three
groups (overall and post hoc comparisons = NS). End
systolic volumes were significantly different between the 3
groups (p = 0.029), with higher volumes in the Q-STEMI
vs. NSTEMI groups (p < 0.05). LV ejection fraction was
also significantly different between the 3 groups (p <
0.0001), with greater values in the NSTEMI group vs. both
Non-Q STEMI (p < 0.001) and Q-STEMI (p < 0.001).
Example images of study patients with NSTEMI, Non-Q
STEMI and Q-STEMI are given in Figure 1. They illustrate
the different extent of scar and ischemia in the three
patient groups.
Table 1: Demographics and presenting characteristics of patients in the three study groups.
NSTEMI (n = 25) Non-Q STEMI (n = 25) Q-STEMI (n = 25)
Age – yr 57 (± 9.3) 60 (± 9.1) 57 (± 8.9)
Male 22 (88%) 20 (80%) 23 (92%)
Risk factors – no. (%)
Diabetes mellitus 5 (20%) 1 (4%) 6 (24%)
Hypertension 9 (36%) 3 (12%) 4 (16%)
Known CAD 3 (12%) 2 (8%) 2 (8%)
Family history of CAD 13 (52%) 8 (32%) 10 (40%)
Current smoker 12 (48%) 12 (48%) 15 (60%)
Previous revascularisation 0 0 0
Presenting characteristics
Systolic BP (mmHg) 129 (± 17.1) 133 (± 21.7) 128 (± 18.8)
TIMI score* 2.7 (± 1.4) 2.1 (± 1.4) 2.7 (± 2.1)
*The TIMI risk scores for NSTEMI and STEMI are different, so that the only statistical comparison is between Non-Q STEMI and Q-STEMI 
(unpaired t-test). CAD = coronary heart disease; BP = blood pressure.
Table 2: Biomarkers, LV volumes, LV mass, ischemia and scar burden in the three study groups.
A 
NSTEMI (n = 25)
B 
Non-Q STEMI (n = 25)
C 
Q-STEMI (n = 25)
A vs B 
p*
A vs C 
p*
B vs C 
p*
Troponin I (mg/ml) 5.9 (± 15.7) 29.6 (± 30.3) 69.9 (± 60.4) >0.05 <0.001 <0.05
Peak CK (IU) 396 (± 421.8) 1289 (± 818) 2253 (± 1524) <0.05 <0.001 <0.01
Anterior MI - 8 12
Inferior/lateral MI - 17 13
LVEDV (ml) 172.5 (± 51.3) 175.0 (± 40.8) 186.9 (± 29.3) >0.05 >0.05 >0.05
LVESV (ml) 80.0 (± 44.8) 94.9 (± 32.5) 107.1 (± 25.1) >0.05 <0.05 >0.05
LV EF (%) 55.5 (± 9.5) 46.6 (± 7.3) 43.1 (± 7.8) <0.001 <0.001 >0.05
LV mass (g) 133.1 (± 36.3) 115.3 (± 26.7) 131.7 (± 24.9) >0.05 >0.05 >0.05
Scar % 3.8 (± 5.3) 15.2 (± 8.4) 24.1 (± 12.6) <0.001 <0.001 <0.01
Ischemia % 19.9 (± 20.1) 14.7 (± 12.6) 6.9 (± 11.4) >0.05 <0.01 >0.05
Data presented as mean ± SD.
* All statistical comparisons by ANOVA post hoc tests. CK = creatine kinase; LV = left ventricle; EDV = end diastolic volume; ESV = end systolic 
volume; EF = ejection fraction.Journal of Cardiovascular Magnetic Resonance 2008, 10:47 http://www.jcmr-online.com/content/10/1/47
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Scar burden
All patients with Q-STEMI and Non-Q STEMI had evi-
dence of myocardial scar on late gadolinium-enhance-
ment images, whilst 7 (28%) NSTEMI patients showed no
focal scar. The scar burden expressed as percentage of LV
mass was significantly different between the 3 groups (p <
0.0001), and was largest in Q-STEMI, followed by Non-Q
STEMI and NSTEMI (Table 2). In 20 (80%) of the patients
with Q-STEMI and 20 (80%) of the Non-Q STEMI
patients the scar was more than 75% in transmural extent
in at least one segment, whilst only one (4%) patient with
NSTEMI showed transmural scar.
Ischemia and total myocardium at risk
Ten (40%) patients with Q-STEMI, 19 (76%) patients
with Non-Q STEMI and 15 (60%) patients with NSTEMI
had evidence of inducible ischemia on stress-perfusion
CMR (p = 0.03). The volume of ischemia was lowest in Q-
STEMI, followed by Non-Q STEMI and NSTEMI (6.9%,
14.7% and 19.9% of LV mass, respectively; p = 0.012);
Table 2.
Scar and ischemia burden combined accounted for 31%
of total LV mass in Q-STEMI, 29.9% for Non-Q STEMI
and 23.1% for NSTEMI, (p = 0.17); (Figure 2). The ratio
of scar to ischemia was 3.5, 1.0 and 0.2 for Q-STEMI, Non-
Q STEMI and NSTEMI, respectively.
Correlation analyses
Peak CK and percent LV infarct mass were significantly
positively correlated (r = 0.85, p < 0.0001). Troponin-I
and percent LV infarct mass were less strongly correlated
(r = 0.65, p < 0.0001). For ejection fraction and percent LV
infarct mass there was a significant negative correlation (r
= -0.65, p < 0.0001).
Discussion
This study provides in-vivo confirmation of the patho-
physiological differences between different types of acute
myocardial infarction. The data show that the ratio of scar
to ischemia varies significantly, with STEMI leading to
larger infarcts than NSTEMI, and that Q-STEMI is associ-
ated with a higher scar burden than Non-Q STEMI. Con-
versely, ischemia burden is lower after Q-STEMI than in
both Non-Q STEMI and NSTEMI. Combined however,
the total mass of scar and ischemic myocardium at risk is
similar between all three types of infarction.
Unlike previous studies that have relied primarily on
biomarkers to determine infarct size or nuclear scintigra-
phy with its limited spatial resolution, measurements
were derived using high resolution CMR. Importantly,
because of the clinical protocols at the time of the study,
we were able to obtain imaging data prior to any revascu-
larisation procedures so that residual inducible ischemia
in the infarct-related artery territory could be determined.
Increasingly, patients with STEMI undergo primary angi-
oplasty and NSTEMI patients are rapidly referred for ang-
iography-guided revascularisation, so that comparable
studies to this will be difficult to conduct in the future.
Table 3: X-ray angiographic results of patients in the three study groups.
NSTEMI (n = 25) Non-Q STEMI (n = 19) Q-STEMI (n = 18)
Vessels with stenosis >70%
LMS 1 (4%) 0 0
LAD 9 (36%) 8 (42%) 10 (55%)
Cx 10 (40%) 9 (47%) 6 (33%)
RCA 9 (36%) 6 (32%) 5 (28%)
Culprit lesion
LMS 1 (4%) 0 0
LAD 9 (36%) 7(37%) 10 (55%)
Cx 5 (20%) 8(42%) 4 (21%)
RCA 5 (20%) 4(21%) 4 (21%)
Disease extent
Minor atheroma only 5 4 3
Single vessel 14 (56%) 8 (42%) 9 (50%)
Two-vessel 4 (16%) 6 (31%) 6 (33%)
Three vessel 2 (8%) 1 (5%) 0
LMS = left main stem; LAD = left anterior descending artery; Cx = circumflex artery; RCA = right coronary artery.Journal of Cardiovascular Magnetic Resonance 2008, 10:47 http://www.jcmr-online.com/content/10/1/47
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STEMI versus NSTEMI
The main finding from this study was that the combined
scar and ischemic myocardial mass was similar between
patients with STEMI and NSTEMI, and only the ratio of
ischemia versus scar differed. While previous separate
studies in STEMI and NSTEMI have shown larger infarct
size in STEMI [4-6], the current study provides the first
direct in-vivo comparison of infarct size between these
two sub-types of acute MI. In our population, patients
with STEMI had more transmural scars and on average a
significantly larger infarct mass than patients with
NSTEMI. Ejection fraction inversely mirrored the scar
mass and was significantly lower early after STEMI than
after NSTEMI. These observations confirm the theory that
in the absence of adequate collateral supply, myocardial
necrosis expands for as long as the coronary occlusion per-
Column A = Late gadolinium-enhancement CMR in the short axis Figure 1
Column A = Late gadolinium-enhancement CMR in the short axis.Column B = Rest perfusion CMR at peak myocardial 
enhancement in the identical location. Column C = Adenosine stress perfusion CMR with identical image parameters to column 
B. Column D = Corresponding X-ray coronary angiogram. Top Row = Example of Q-wave STEMI, showing a large septal scar 
with a central area of microvascular obstruction (A; full arrow). There is also a small inferior scar (A; dotted arrow). Rest per-
fusion CMR (B) shows a defect corresponding predominantly to the area of the microvascular obstruction. Stress perfusion 
CMR (C) shows the perfusion defect in the entire infarct and extending marginally into the peri-infarct zone. Coronary angiog-
raphy (D) revealed an occluded proximal LAD at the site of a previous stent. Middle Row = Example of Non Q-wave STEMI, 
showing a small inferior scar (A; arrow). Rest perfusion CMR (B) shows the small inferior scar is not detected as a fixed per-
fusion defect. The stress perfusion image (C) shows a large inducible perfusion defect infero-laterally, extending beyond the 
scar into the peri-infarct zone (C; arrow). The coronary angiogram (D) shows a severe stenosis in the mid circumflex artery. 
Bottom Row = Example of NSTEMI, showing a small subendocardial scar in the antero-septal segment (A). Rest perfusion CMR 
(B) appears homogenous outside the scar. The stress perfusion image (C) shows a large area of inducible antero-septal 
ischemia. On coronary angiography (D), severe disease in the left anterior descending artery was found.Journal of Cardiovascular Magnetic Resonance 2008, 10:47 http://www.jcmr-online.com/content/10/1/47
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sists. The occlusive thrombus responsible for STEMI there-
fore causes larger infarcts than the transient coronary
occlusion or distal embolisation responsible for NSTEMI.
Ischemia burden on the other hand was both more com-
mon and more extensive in the NSTEMI group than in
either of the STEMI groups. This finding is biologically
plausible as the total perfusion zone of the infarct related
arteries will be similar between STEMI and NSTEMI.
Because in STEMI more myocardium is infarcted, less tis-
sue is left at ischemic risk after the acute event.
Q-STEMI versus Non-Q STEMI
In approximately one third of patients suffering a STEMI
pathological Q-waves do not develop on the post-infarct
electrocardiogram [7,8]. It is now widely accepted that the
development of Q-waves is mainly a reflection of infarct
size [9,10]. Potential pathophysiologic mechanisms for
the smaller infarct size in Non-Q STEMI include a shorter
duration of ischemia, a lower thrombus burden and more
distal stenosis. In our study, patients with Non-Q STEMI
formed an 'intermediate' group compared to Q-STEMI
and NSTEMI in terms of infarct size, LV function and
residual inducible ischemia. The presenting characteris-
tics, infarct location and angiographic features were simi-
lar in Q-STEMI and Non-Q STEMI patients. Only time to
treatment was shorter in Non-Q STEMIs, although this
difference did not reach statistical significance and no dif-
ference in time to treatment was seen in previous larger
studies [8]. Our results are in accord with prior observa-
tions that scar size is smaller in Non-Q STEMI, ejection
fraction is higher and cardiac enzyme release is less than
in Q-STEMI [7,8].
Previously, Q-wave and Non-Q-wave MI have been com-
pared by nuclear scintigraphy methods. As long as 20
years ago, Gibons et al., reported less segments with per-
sistent 201Tl defects and more segments with redistribu-
tion defects during stress in Non-Q-wave MI than Q-wave
MI [11]. More recently, Yang et al., reported higher
ischemia burden in Non-Q-wave than Q-wave MI using
positron emission tomography, but in contradiction to
both our study and Gibons' results, they observed no sig-
nificant difference in scar burden between the two types of
MI [12]. Whilst differences in patient selection between
our study and Yang's study may be partly responsible for
these discrepant results, importantly, in our study the
high spatial resolution of CMR allowed scar and ischemia
to be measured in absolute grams of tissue rather than by
myocardial segments as is custom in nuclear scintigraphy.
Our results should thus give a more accurate reflection of
the pathological effects of different types of acute infarc-
tion than the previous literature.
Limitations
Stress perfusion imaging will only reveal ischemia in
those patients with an underlying flow-limiting coronary
stenosis. It is well recognized that a significant proportion
of acute coronary syndromes arise from plaques that are
not flow-limiting [2]. The true prevalence of flow-limiting
disease in our population is not fully known because not
all STEMI patients underwent coronary angiography and
invasive pressure wire measurements were not performed.
In those patients who had angiography however, approx-
imately 20% in all three study groups had no coronary ste-
nosis of greater than 70% severity.
The stress perfusion sequence did not allow full LV cover-
age. Even after correcting for this with data interpolation,
there is still the possibility that inducible ischaemia could
have been missed from a true basal or apical slice. This
would likely have impacted most on the NSTEMI group
where the ischaemic burden was greatest; indeed the com-
bined scar and inducible ischaemia mass in this group was
less (Figure 2) than the other two groups.
Finally, there will always be individual variation as to the
mass of myocardium supplied by a particular coronary
artery and also the size of the 'territory at risk' depending
on the location of acute lesion. Although this can never be
strictly controlled for in human studies, there were no sig-
nificant differences in angiographic characteristics
between our three groups.
Scar and ischemia burden Figure 2
Scar and ischemia burden. Scar and inducible ischemia 
burden in Q-STEMI, Non-Q STEMI and NSTEMI expressed 
as percentage of LV mass.Journal of Cardiovascular Magnetic Resonance 2008, 10:47 http://www.jcmr-online.com/content/10/1/47
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Clinical implications
In STEMI the risk of adverse events is considered highest
during the acute presentation, likely related to the larger
scar mass and lower ejection fraction, whilst relatively less
myocardium remains at long-term ischemic risk. However
in patients with NSTEMI, despite an initial lower risk, car-
diovascular events in the longer term are at least as fre-
quent, if not more so, compared to STEMI [23-28]. The
results of this study support the notion that patients with
NSTEMI lose their initial prognostic advantage, as more
viable tissue in the territory of the infarct-related artery
remains at ischemic risk [14]. Even though a proportion
of culprit lesions are not flow-limiting, inducible ischemia
is more common after NSTEMI and than after Q-STEMI.
Early revascularisation can thus improve prognosis after
NSTEMI by removing the substrate for subsequent
ischemic events, and is recommended in current manage-
ment guidelines [29].
Conclusion
This study has demonstrated that clear differences exist in
the mass of scar and ischemic myocardium at risk between
Q-STEMI, Non-Q STEMI and NSTEMI, whilst overall the
combined mass of ischemic and scar tissue was similar.
The greater mass of inducible ischemic tissue in NSTEMI
patients may be one of the factors responsible for their
high late cardiovascular event rate, if appropriate revascu-
larisation is not undertaken.
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